- spreading risk across various therapeutic and disease areas and across various development stages.
| Therapeutic Area |
Drug |
Action |
Disease / Condition |
Stage |
Estimated date |
Partner |
| Cardiovascular |
Generic fondaparinux |
Indirect factor Xa inhibitor |
VTE |
ANDA filed and accepted |
2009 CY / FDA approval
2009 CY / Market launch |
Dr Reddy’s |
| Oncology |
HA-irinotecan |
Topoisomerase I inhibitor |
Colorectal Cancer |
Clinical - Ph III IND accepted by the US FDA |
2010 CY commence Phase III |
|
| Oncology |
HyACT® antibodies |
Various |
Cancer |
Preclinical |
- |
|
| Neuroscience |
VAST® various |
Opioid agonist |
Pain |
Discovery |
- |
University of Queensland |
| Neuroscience |
VAST® various |
MCHR1 anatagonist |
Obesity |
Discovery |
- Program suspended due to funding constraints |
|
| Respiratory |
VAST® various |
Undisclosed |
Respiratory |
Discovery |
- Program suspended due to funding constraints |
|
Discovery - chemical compounds with possible therapeutic benefit in man are identified
Preclinical - compound/treatments are tested to measure efficacy and safety prior to testing in humans
Clinical - structured studies are conducted in a hospital or clinic in which a drug is evaluated for its effects on humans |
